25/10/2010
Afghanistan
New bivalent polio vaccine playing key role in global polio eradication
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3) vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.
For details, please go to:
http://www.thelancet.com
Related News
30/04/2024
Across Afghanistan, community advocacy to increase vaccine uptake for polio and other deadly diseases has some unsung champions: the local women
28/04/2024
New commitment will help vaccinate 370 million children against polio over five years, preventing paralysis and even death, and strengthen health systems to achieve and sustain a polio-free world.
26/04/2024
President and First Lady meet with GPEI delegation to discuss measures to increase immunity levels
24/04/2024
By Dr Hamid Jafari, Director, Polio Eradication, WHO Eastern Mediterranean Region
22/04/2024
World Immunization Week highlights the importance of immunization globally
